Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

827
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
827
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

118
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
118
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K
Proteoglycans01:05

Proteoglycans

4.0K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
4.0K
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

643
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
643

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonfactor Replacement Treatment and Surgery in Haemophilia: Evidence From the Literature and Selected Clinical Cases.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool.

Journal of clinical medicine·2026
Same author

Glucosylsphingosine (Lyso-Gb1): An Update on Its Use as a Biomarker in Gaucher Disease.

International journal of molecular sciences·2026
Same author

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.

Blood advances·2026
Same author

International Practices in Managing Preconception, Pregnancy and Childbirth in Women With Glanzmann Thrombasthenia: A Survey From the European Association of Haemophilia and Allied Disorders (EAHAD).

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

Supporting Patient-Centred Decisions on Gene Therapy for Haemophilia A: A Conceptual Model.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Related Experiment Video

Updated: Aug 18, 2025

Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

13.8K

Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications.

Silvia Linari1, Giancarlo Castaman1

  • 1Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy.

Journal of Clinical Medicine
|December 11, 2022
PubMed
Summary

Gaucher disease (GD) involves impaired metabolism leading to bleeding risks due to hemostasis issues. Treatments like enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) can improve these hematological symptoms.

Keywords:
Gaucher diseasebleedingclotting factorshemostasisplatelets

More Related Videos

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.1K
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.5K

Related Experiment Videos

Last Updated: Aug 18, 2025

Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

13.8K
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.1K
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.5K

Area of Science:

  • Biochemistry
  • Genetics
  • Hematology

Background:

  • Gaucher disease (GD) is a rare inherited lysosomal storage disorder.
  • It results from accumulating lipids like β-glucosylceramide, causing inflammation and multi-organ dysfunction.
  • Type 1 GD is most common, presenting with varied severity and significant hematological involvement.

Purpose of the Study:

  • To summarize the pathophysiology of Gaucher disease, focusing on hematological manifestations and hemostasis abnormalities.
  • To review the current treatment options for Gaucher disease and their impact on hemostatic defects.

Main Methods:

  • Literature review of Gaucher disease pathophysiology and hematological complications.
  • Analysis of treatment efficacy for hemostatic abnormalities in Gaucher disease.

Main Results:

  • Gaucher disease causes bleeding tendencies due to thrombocytopenia, platelet dysfunction, and clotting factor abnormalities.
  • Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) effectively improve hematological and hemostatic abnormalities.
  • Additional hemostatic medications may be beneficial in specific clinical scenarios.

Conclusions:

  • Hematological and hemostatic abnormalities are key features of Gaucher disease, contributing to bleeding risk.
  • ERT and SRT are crucial for managing these complications.
  • Careful management of hemostasis is essential, especially during surgery or delivery.